(0.38%) 5 119.14 points
(0.35%) 38 372 points
(0.49%) 16 005 points
(-1.38%) $82.69
(4.94%) $2.02
(0.40%) $2 356.70
(0.45%) $27.66
(4.63%) $964.80
(-0.25%) $0.932
(-0.40%) $10.98
(-0.57%) $0.796
(1.70%) $93.44
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.54%
3.92% $ 2.26
@ $1.790
Emitido: 14 feb 2024 @ 09:30
Retorno: 25.98%
Señal anterior: feb 13 - 09:30
Señal anterior:
Retorno: 1.71 %
Live Chart Being Loaded With Signals
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness...
Stats | |
---|---|
Volumen de hoy | 175 270 |
Volumen promedio | 911 022 |
Capitalización de mercado | 574.88M |
EPS | $0 ( 2024-02-27 ) |
Próxima fecha de ganancias | ( $-0.200 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.42 |
ATR14 | $0.00400 (0.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-09 | Lang Matthew | Buy | 500 000 | Option (right to buy) |
2024-02-09 | Lang Matthew | Buy | 50 000 | Common Stock |
2024-02-09 | Hill Stephen J. | Buy | 400 000 | Stock Option (right to buy) |
2024-02-09 | Hill Stephen J. | Buy | 40 000 | Common Stock |
2024-02-09 | Lee Gary K. | Buy | 400 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
39.75 |
Last 94 transactions |
Buy: 113 687 542 | Sell: 91 558 207 |
Volumen Correlación
Lyell Immunopharma, Inc. Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Lyell Immunopharma, Inc. Correlación - Moneda/Commodity
Lyell Immunopharma, Inc. Finanzas
Annual | 2023 |
Ingresos: | $130 000 |
Beneficio Bruto: | $-20.12M (-15 476.92 %) |
EPS: | $-0.930 |
FY | 2023 |
Ingresos: | $130 000 |
Beneficio Bruto: | $-20.12M (-15 476.92 %) |
EPS: | $-0.930 |
FY | 2022 |
Ingresos: | $84.68M |
Beneficio Bruto: | $68.22M (80.55 %) |
EPS: | $-0.0192 |
FY | 2021 |
Ingresos: | $10.65M |
Beneficio Bruto: | $10.65M (100.00 %) |
EPS: | $-1.249 |
Financial Reports:
No articles found.
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico